RU2020116579A - Способы получения клеток, экспрессирующих химерный антигенный рецептор - Google Patents
Способы получения клеток, экспрессирующих химерный антигенный рецептор Download PDFInfo
- Publication number
- RU2020116579A RU2020116579A RU2020116579A RU2020116579A RU2020116579A RU 2020116579 A RU2020116579 A RU 2020116579A RU 2020116579 A RU2020116579 A RU 2020116579A RU 2020116579 A RU2020116579 A RU 2020116579A RU 2020116579 A RU2020116579 A RU 2020116579A
- Authority
- RU
- Russia
- Prior art keywords
- molecules
- stat3
- car
- population
- cell
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 85
- 230000000890 antigenic effect Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims 140
- 101150099493 STAT3 gene Proteins 0.000 claims 110
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 92
- 230000004913 activation Effects 0.000 claims 40
- 239000012190 activator Substances 0.000 claims 40
- 239000012642 immune effector Substances 0.000 claims 40
- 229940121354 immunomodulator Drugs 0.000 claims 40
- 230000004153 glucose metabolism Effects 0.000 claims 37
- 108020004707 nucleic acids Proteins 0.000 claims 27
- 102000039446 nucleic acids Human genes 0.000 claims 27
- 150000007523 nucleic acids Chemical class 0.000 claims 27
- 239000011541 reaction mixture Substances 0.000 claims 22
- 230000034659 glycolysis Effects 0.000 claims 21
- 239000003112 inhibitor Substances 0.000 claims 21
- 230000004044 response Effects 0.000 claims 20
- 102000004889 Interleukin-6 Human genes 0.000 claims 18
- 108090001005 Interleukin-6 Proteins 0.000 claims 18
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 claims 16
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 10
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 102000004127 Cytokines Human genes 0.000 claims 9
- 108090000695 Cytokines Proteins 0.000 claims 9
- 102100033096 Interleukin-17D Human genes 0.000 claims 9
- 229940122084 Hexokinase inhibitor Drugs 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 150000002303 glucose derivatives Chemical class 0.000 claims 8
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims 7
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims 7
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims 7
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 claims 7
- 230000001900 immune effect Effects 0.000 claims 7
- 102100020989 Interferon lambda-2 Human genes 0.000 claims 6
- 101710099622 Interferon lambda-2 Proteins 0.000 claims 6
- 102000003815 Interleukin-11 Human genes 0.000 claims 6
- 102100033101 Interleukin-17B Human genes 0.000 claims 6
- 230000001965 increasing effect Effects 0.000 claims 6
- 230000026731 phosphorylation Effects 0.000 claims 6
- 238000006366 phosphorylation reaction Methods 0.000 claims 6
- 102100036848 C-C motif chemokine 20 Human genes 0.000 claims 5
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 claims 5
- 102100020992 Interferon lambda-3 Human genes 0.000 claims 5
- 101710099621 Interferon lambda-3 Proteins 0.000 claims 5
- 102100033461 Interleukin-17A Human genes 0.000 claims 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 5
- 238000003556 assay Methods 0.000 claims 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 5
- 102100027207 CD27 antigen Human genes 0.000 claims 4
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 4
- 102100021596 Interleukin-31 Human genes 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 150000001413 amino acids Chemical group 0.000 claims 4
- 238000004458 analytical method Methods 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000019491 signal transduction Effects 0.000 claims 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 3
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 3
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims 3
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims 3
- 101000998181 Homo sapiens Interleukin-17B Proteins 0.000 claims 3
- 101000998178 Homo sapiens Interleukin-17C Proteins 0.000 claims 3
- 101000998176 Homo sapiens Interleukin-17D Proteins 0.000 claims 3
- 101000998151 Homo sapiens Interleukin-17F Proteins 0.000 claims 3
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 claims 3
- 102000039989 IL-17 family Human genes 0.000 claims 3
- 108091069193 IL-17 family Proteins 0.000 claims 3
- 102100033105 Interleukin-17C Human genes 0.000 claims 3
- 102100033454 Interleukin-17F Human genes 0.000 claims 3
- 102100036680 Interleukin-25 Human genes 0.000 claims 3
- 101710181613 Interleukin-31 Proteins 0.000 claims 3
- 102000010781 Interleukin-6 Receptors Human genes 0.000 claims 3
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims 3
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 3
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims 3
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims 3
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 claims 3
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 claims 3
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims 3
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims 3
- 239000000539 dimer Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims 3
- 108091006084 receptor activators Proteins 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 108050003558 Interleukin-17 Proteins 0.000 claims 2
- 241000713666 Lentivirus Species 0.000 claims 2
- 230000008859 change Effects 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000037323 metabolic rate Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 238000004806 packaging method and process Methods 0.000 claims 2
- 230000002103 transcriptional effect Effects 0.000 claims 2
- QUTFFEUUGHUPQC-ILWYWAAHSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC1=CC=C([N+]([O-])=O)C2=NON=C12 QUTFFEUUGHUPQC-ILWYWAAHSA-N 0.000 claims 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 claims 1
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 claims 1
- 108010005327 CD19-specific chimeric antigen receptor Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101001043821 Homo sapiens Interleukin-31 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000686034 Homo sapiens Nuclear receptor ROR-gamma Proteins 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 102100023421 Nuclear receptor ROR-gamma Human genes 0.000 claims 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 238000006471 dimerization reaction Methods 0.000 claims 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 238000005734 heterodimerization reaction Methods 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000008054 signal transmission Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 108010078373 tisagenlecleucel Proteins 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/231—Interleukin-10 (IL-10)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2311—Interleukin-11 (IL-11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2317—Interleukin-17 (IL-17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2319—Interleukin-19 (IL-19)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2322—Interleukin-22 (IL-22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2323—Interleukin-23 (IL-23)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2324—Interleukin-24 (IL-24)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2326—Interleukin-26 (IL-26)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2328—Interleukin-28 (IL-28)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physiology (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762577099P | 2017-10-25 | 2017-10-25 | |
| US62/577,099 | 2017-10-25 | ||
| US201862637854P | 2018-03-02 | 2018-03-02 | |
| US62/637,854 | 2018-03-02 | ||
| PCT/US2018/057545 WO2019084288A1 (en) | 2017-10-25 | 2018-10-25 | METHODS FOR DESIGNING CHIMERIC ANTIGENIC RECEPTOR EXPRESSION CELLS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2020116579A true RU2020116579A (ru) | 2021-11-25 |
Family
ID=64650463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020116579A RU2020116579A (ru) | 2017-10-25 | 2018-10-25 | Способы получения клеток, экспрессирующих химерный антигенный рецептор |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20200370012A1 (https=) |
| EP (1) | EP3700926A1 (https=) |
| JP (1) | JP2021500894A (https=) |
| KR (1) | KR20200069358A (https=) |
| CN (1) | CN111566124A (https=) |
| AU (1) | AU2018355427A1 (https=) |
| BR (1) | BR112020007710A2 (https=) |
| CA (1) | CA3078270A1 (https=) |
| IL (1) | IL273956A (https=) |
| MX (1) | MX2020004229A (https=) |
| RU (1) | RU2020116579A (https=) |
| SG (1) | SG11202003177RA (https=) |
| WO (1) | WO2019084288A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6647868B2 (ja) | 2013-02-20 | 2020-02-14 | ノバルティス アーゲー | ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置 |
| WO2014145252A2 (en) | 2013-03-15 | 2014-09-18 | Milone Michael C | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| WO2015112626A1 (en) | 2014-01-21 | 2015-07-30 | June Carl H | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| BR112017001183A2 (pt) | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| MX2017002205A (es) | 2014-08-19 | 2017-08-21 | Novartis Ag | Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer. |
| JP6961490B2 (ja) | 2015-04-08 | 2021-11-05 | ノバルティス アーゲー | Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法 |
| AU2016249005B2 (en) | 2015-04-17 | 2022-06-16 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| CA2992551A1 (en) | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| WO2017040930A2 (en) | 2015-09-03 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
| EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| BR112019006781A2 (pt) | 2016-10-07 | 2019-07-30 | Novartis Ag | receptores de antígeno quiméricos para o tratamento de câncer |
| ES2912408T3 (es) | 2017-01-26 | 2022-05-25 | Novartis Ag | Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos |
| AU2018351050B2 (en) | 2017-10-18 | 2025-09-18 | Novartis Ag | Compositions and methods for selective protein degradation |
| US12539308B2 (en) | 2018-01-08 | 2026-02-03 | The Trustees Of The University Of Pennsylvania | Immune-enhancing RNAs for combination with chimeric antigen receptor therapy |
| TWI890660B (zh) | 2018-06-13 | 2025-07-21 | 瑞士商諾華公司 | Bcma 嵌合抗原受體及其用途 |
| CN109735558B (zh) * | 2018-12-12 | 2022-04-15 | 中南大学 | 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用 |
| US12419913B2 (en) | 2019-02-08 | 2025-09-23 | Dna Twopointo, Inc. | Modification of CAR-T cells |
| CN110272493A (zh) * | 2019-06-05 | 2019-09-24 | 南京凯地生物科技有限公司 | 靶向cd19的特异性嵌合抗原受体t细胞及其制备方法和临床应用 |
| CN110331134B (zh) * | 2019-07-19 | 2023-09-08 | 上海交通大学医学院附属瑞金医院 | 一种表达抗原识别区域的通用型细胞治疗产品及其制备方法和应用 |
| EP4065157A1 (en) | 2019-11-26 | 2022-10-05 | Novartis AG | Cd19 and cd22 chimeric antigen receptors and uses thereof |
| IL293215A (en) | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors that bind bcma and cd19 and their uses |
| WO2021119349A1 (en) * | 2019-12-10 | 2021-06-17 | Refuge Biotechnologies, Inc. | Chimeric receptor polypeptide and methods of activation thereof |
| WO2021150919A1 (en) | 2020-01-23 | 2021-07-29 | The Children's Medical Center Corporation | Stroma-free t cell differentiation from human pluripotent stem cells |
| JP7626780B2 (ja) * | 2020-04-15 | 2025-02-04 | アムジエン・インコーポレーテツド | 遺伝子改変自己ｔ細胞を製造するためのプロセス |
| US12378521B2 (en) | 2020-04-15 | 2025-08-05 | Amgen Inc. | Method for enhancing production of genetically engineered autologous T cells |
| US12241086B2 (en) | 2020-04-15 | 2025-03-04 | Amgen Inc. | Process for generating genetically engineered autologous T cells |
| WO2022095902A1 (en) * | 2020-11-03 | 2022-05-12 | Hangzhou Qihan Biotechnology Co., Ltd. | Systems and methods for enhanced immunotherapies |
| WO2022180586A1 (en) * | 2021-02-25 | 2022-09-01 | Senthil Natesan | Car t-cell product and method of preparation thereof |
| TW202325844A (zh) * | 2021-11-03 | 2023-07-01 | 中國大陸商杭州啟函生物科技有限公司 | 增強免疫療法的系統和方法 |
| CN116178562A (zh) * | 2021-11-29 | 2023-05-30 | 四川大学华西医院 | 基于efna1构建的嵌合抗原受体免疫细胞制备及其应用 |
| US20240315237A1 (en) * | 2023-02-17 | 2024-09-26 | Abbott Diabetes Care Inc. | Methods for single cell analysis of glucose internalization |
Family Cites Families (139)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0090505B1 (en) | 1982-03-03 | 1990-08-08 | Genentech, Inc. | Human antithrombin iii, dna sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin iii, and pharmaceutical compositions comprising it |
| US4851332A (en) | 1985-04-01 | 1989-07-25 | Sloan-Kettering Institute For Cancer Research | Choriocarcinoma monoclonal antibodies and antibody panels |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| US5646253A (en) | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| EP0679660A4 (en) | 1993-11-16 | 2000-08-16 | Pola Chem Ind Inc | MONOCLONAL ANTIBODY AGAINST HUMAN TYROSINASE |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| EP0756604A1 (en) | 1994-04-22 | 1997-02-05 | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services | Melanoma antigens |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| ATE186745T1 (de) | 1995-01-18 | 1999-12-15 | Roche Diagnostics Gmbh | Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| AU731826B2 (en) | 1996-02-28 | 2001-04-05 | Ariad Pharmaceuticals, Inc. | Synthetic Multimerizing Agents |
| DE19608769C1 (de) | 1996-03-07 | 1997-04-10 | Univ Eberhard Karls | Antikörper BV10A4H2 |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| ES2308787T3 (es) | 1996-08-16 | 2008-12-01 | Schering Corporation | Antigenos de superficie de celular de mamiferos; reactivos relacionados. |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| EP0938557B1 (en) | 1996-10-25 | 2000-09-13 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian cd97 alpha subunit |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| JP2001520039A (ja) | 1997-10-21 | 2001-10-30 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ヒト腫瘍壊死因子レセプター様タンパク質、ｔｒ１１，ｔｒ１１ｓｖ１およびｔｒ１１ｓｖ２ |
| AU2591599A (en) | 1998-02-09 | 1999-08-23 | Genentech Inc. | Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same |
| US20040040047A1 (en) | 1998-03-30 | 2004-02-26 | Spencer David M. | Regulated apoptosis using chemically induced dimerization of apoptosis factors |
| US6803448B1 (en) | 1998-07-22 | 2004-10-12 | Vanderbilt University | GBS toxin receptor |
| US6528481B1 (en) | 1999-02-16 | 2003-03-04 | The Burnam Institute | NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods |
| WO2001003720A2 (en) | 1999-07-12 | 2001-01-18 | Genentech, Inc. | Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| DE60038252T2 (de) | 1999-09-30 | 2009-03-19 | Kyowa Hakko Kogyo Co., Ltd. | Menschlicher Antikörper gegen Gangliosid GD3 für die Transplantationskomplentarität bestimmende Region und Derivate des Antikörpers gegen das Gangliosid GD3 |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| PT1419179E (pt) | 2001-08-10 | 2010-03-16 | Univ Aberdeen | Domínios de ligação de antigenes |
| ES2736165T3 (es) | 2001-08-23 | 2019-12-26 | Rsr Ltd | Regiones epítopo de un receptor de tirotropina (TSH), sus usos y anticuerpos para las mismas |
| WO2003048337A2 (en) | 2001-12-04 | 2003-06-12 | Dana-Farber Cancer Institute, Inc. | Antibody to latent membrane proteins and uses thereof |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| DE50306067D1 (de) | 2002-11-26 | 2007-02-01 | Brahms Ag | Nachweis von tsh-rezeptor-autoantikörpern mit affinitätsgereinigten antikörpern |
| WO2004087758A2 (en) | 2003-03-26 | 2004-10-14 | Neopharm, Inc. | Il 13 receptor alpha 2 antibody and methods of use |
| CU23403A1 (es) | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
| US7618632B2 (en) | 2003-05-23 | 2009-11-17 | Wyeth | Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies |
| EP1646357A4 (en) | 2003-06-27 | 2007-01-10 | Diadexus Inc | PRO104 ANTIBODY COMPOSITIONS AND APPLICATION PROCEDURES |
| KR20060041205A (ko) | 2003-07-01 | 2006-05-11 | 이뮤노메딕스, 인코오포레이티드 | 양특이성 항체들의 다가 담체들 |
| WO2005007190A1 (en) | 2003-07-11 | 2005-01-27 | Schering Corporation | Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer |
| JPWO2005035577A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | ガングリオシドｇｄ３に特異的に結合する抗体組成物 |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| WO2005055808A2 (en) | 2003-12-02 | 2005-06-23 | Genzyme Corporation | Compositions and methods to diagnose and treat lung cancer |
| AU2005235811B2 (en) | 2004-02-06 | 2011-11-03 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
| GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| WO2005118788A2 (en) | 2004-05-27 | 2005-12-15 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| US20060002932A1 (en) | 2004-06-04 | 2006-01-05 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| EP1786918A4 (en) | 2004-07-17 | 2009-02-11 | Imclone Systems Inc | NEW BISPECIFIC ANTIBODY TETRAVALENT |
| MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| EP1726650A1 (en) | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
| NZ564098A (en) | 2005-06-15 | 2010-04-30 | Schering Corp | Anti-IGF1R antibody formulations |
| NZ612578A (en) | 2005-08-19 | 2014-11-28 | Abbvie Inc | Dual variable domain immunoglobin and uses thereof |
| US8383118B2 (en) | 2005-12-08 | 2013-02-26 | Medarex, Inc. | Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1 |
| EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| WO2007133822A1 (en) | 2006-01-19 | 2007-11-22 | Genzyme Corporation | Gitr antibodies for the treatment of cancer |
| CA2646329C (en) | 2006-03-20 | 2018-07-03 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
| JP5165672B2 (ja) | 2006-03-29 | 2013-03-21 | キングス カレッジ ロンドン | Ｔｓｈｒに対するアゴニスト抗体 |
| KR100806107B1 (ko) | 2006-04-11 | 2008-02-21 | 엘지전자 주식회사 | Ｄｒｍ에서의 비보호 콘텐츠의 보호 방법 |
| TWI395754B (zh) | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| AU2007304590A1 (en) | 2006-10-04 | 2008-04-10 | Cancer Research Technology Limited | Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies |
| FR2906808B1 (fr) | 2006-10-10 | 2012-10-05 | Univ Nantes | Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers |
| WO2008101234A2 (en) | 2007-02-16 | 2008-08-21 | Sloan-Kettering Institute For Cancer Research | Anti ganglioside gd3 antibodies and uses thereof |
| WO2008103645A2 (en) | 2007-02-19 | 2008-08-28 | Wisconsin Alumni Research Foundation | Prostate cancer and melanoma antigens |
| EP2144935A2 (en) | 2007-03-29 | 2010-01-20 | Technion Research & Development Foundation Ltd. | Antibodies, methods and kits for diagnosing and treating melanoma |
| JP2010190572A (ja) | 2007-06-01 | 2010-09-02 | Sapporo Medical Univ | ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬 |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| CA2694990A1 (en) | 2007-07-31 | 2009-02-05 | Merck Sharp & Dohme Corp. | Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders |
| WO2009091826A2 (en) * | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| AR071891A1 (es) | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| NZ590667A (en) | 2008-07-02 | 2013-01-25 | Emergent Product Dev Seattle | Tgf-b antagonist multi-target binding proteins |
| CN102149820B (zh) | 2008-09-12 | 2014-07-23 | 国立大学法人三重大学 | 能够表达外源gitr配体的细胞 |
| AU2009293007B2 (en) | 2008-09-19 | 2015-10-08 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| GB0919054D0 (en) | 2009-10-30 | 2009-12-16 | Isis Innovation | Treatment of obesity |
| TR201904484T4 (tr) | 2009-11-03 | 2019-05-21 | Hope City | Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt). |
| AU2010325969B2 (en) | 2009-12-02 | 2016-10-20 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen |
| DK2516468T3 (en) | 2009-12-23 | 2016-05-23 | Synimmune Gmbh | ANTI-FLT3 ANTIBODIES AND METHODS FOR USING THESE |
| CA2785907A1 (en) | 2009-12-29 | 2011-07-28 | Emergent Product Development Seattle, Llc | Ron binding constructs and methods of use thereof |
| TWI622402B (zh) | 2010-02-24 | 2018-05-01 | 免疫遺傳股份有限公司 | 葉酸受體１抗體類和免疫共軛物類及彼等之用途 |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| US9242014B2 (en) | 2010-06-15 | 2016-01-26 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof |
| EP3323830B1 (en) | 2010-06-19 | 2023-08-23 | Memorial Sloan-Kettering Cancer Center | Anti-gd2 antibodies |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2012033885A1 (en) | 2010-09-08 | 2012-03-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered gd2-specific t cells |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| MX2013011363A (es) | 2011-04-01 | 2014-04-25 | Sloan Kettering Inst Cancer | Anticuerpos para peptidos citosolicos. |
| CA2832540C (en) | 2011-04-08 | 2020-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| AR086044A1 (es) | 2011-05-12 | 2013-11-13 | Imclone Llc | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos |
| WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
| EP3326467B1 (en) | 2011-09-16 | 2020-03-11 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| ITMO20110270A1 (it) | 2011-10-25 | 2013-04-26 | Sara Caldrer | Una cellula effettrice modificata per il trattamento di neoplasie esprimenti il disialonganglioside gd2 |
| US10391126B2 (en) | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
| US9439768B2 (en) | 2011-12-08 | 2016-09-13 | Imds Llc | Glenoid vault fixation |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| CA2861491C (en) | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| CA3285826A1 (en) * | 2012-02-22 | 2026-03-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| US9056910B2 (en) | 2012-05-01 | 2015-06-16 | Genentech, Inc. | Anti-PMEL17 antibodies and immunoconjugates |
| WO2013192294A1 (en) | 2012-06-20 | 2013-12-27 | Boston 3T Biotechnologies, Inc. | Cellular therapies for treating and preventing cancers and other immune system disorders |
| WO2014055442A2 (en) | 2012-10-01 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| DK2956175T3 (da) | 2013-02-15 | 2017-11-27 | Univ California | Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf |
| US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
| JP6647868B2 (ja) | 2013-02-20 | 2020-02-14 | ノバルティス アーゲー | ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置 |
| AU2014218667A1 (en) | 2013-02-22 | 2015-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds, compositions, methods, and kits relating to telomere extension |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| CA2905352A1 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| WO2014145252A2 (en) | 2013-03-15 | 2014-09-18 | Milone Michael C | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| US9657105B2 (en) * | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| CA2913052A1 (en) | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| ES2791598T3 (es) | 2013-06-05 | 2020-11-05 | Bellicum Pharmaceuticals Inc | Métodos para inducir apoptosis parcial utilizando polipéptidos de caspasa |
| ES2918501T3 (es) | 2013-12-19 | 2022-07-18 | Novartis Ag | Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| US20170335281A1 (en) | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| AU2015244039B2 (en) | 2014-04-07 | 2021-10-21 | Novartis Ag | Treatment of cancer using anti-CD19 chimeric antigen receptor |
| BR112017001183A2 (pt) | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| SG10201913782UA (en) | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cll-1 chimeric antigen receptor |
| TWI719942B (zh) | 2014-07-21 | 2021-03-01 | 瑞士商諾華公司 | 使用ｃｄ３３嵌合抗原受體治療癌症 |
| AU2015301460B2 (en) | 2014-08-14 | 2021-04-08 | Novartis Ag | Treatment of cancer using GFR alpha-4 chimeric antigen receptor |
| MX2017002205A (es) | 2014-08-19 | 2017-08-21 | Novartis Ag | Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer. |
| CN109153975A (zh) | 2015-12-28 | 2019-01-04 | 诺华股份有限公司 | 制备嵌合抗原受体表达细胞的方法 |
| CN109072196A (zh) * | 2016-01-08 | 2018-12-21 | 罗杰威廉姆斯医疗中心以普拉斯派克特查特凯尔Rwmc有限责任公司许可 | 老年car-t细胞及其用途 |
-
2018
- 2018-10-25 RU RU2020116579A patent/RU2020116579A/ru unknown
- 2018-10-25 CN CN201880068990.9A patent/CN111566124A/zh active Pending
- 2018-10-25 EP EP18815371.2A patent/EP3700926A1/en not_active Withdrawn
- 2018-10-25 KR KR1020207014295A patent/KR20200069358A/ko not_active Ceased
- 2018-10-25 BR BR112020007710-0A patent/BR112020007710A2/pt not_active IP Right Cessation
- 2018-10-25 JP JP2020523416A patent/JP2021500894A/ja active Pending
- 2018-10-25 WO PCT/US2018/057545 patent/WO2019084288A1/en not_active Ceased
- 2018-10-25 CA CA3078270A patent/CA3078270A1/en active Pending
- 2018-10-25 AU AU2018355427A patent/AU2018355427A1/en not_active Abandoned
- 2018-10-25 US US16/759,251 patent/US20200370012A1/en not_active Abandoned
- 2018-10-25 SG SG11202003177RA patent/SG11202003177RA/en unknown
- 2018-10-25 MX MX2020004229A patent/MX2020004229A/es unknown
-
2020
- 2020-04-13 IL IL273956A patent/IL273956A/en unknown
-
2025
- 2025-07-28 US US19/282,534 patent/US20260055157A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL273956A (en) | 2020-05-31 |
| CN111566124A (zh) | 2020-08-21 |
| CA3078270A1 (en) | 2019-05-02 |
| JP2021500894A (ja) | 2021-01-14 |
| US20260055157A1 (en) | 2026-02-26 |
| EP3700926A1 (en) | 2020-09-02 |
| SG11202003177RA (en) | 2020-05-28 |
| MX2020004229A (es) | 2020-07-22 |
| KR20200069358A (ko) | 2020-06-16 |
| BR112020007710A2 (pt) | 2020-10-20 |
| WO2019084288A1 (en) | 2019-05-02 |
| US20200370012A1 (en) | 2020-11-26 |
| AU2018355427A1 (en) | 2020-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020116579A (ru) | Способы получения клеток, экспрессирующих химерный антигенный рецептор | |
| AU2016349724A1 (en) | Chimeric receptors containing TRAF-inducing domains and related compositions and methods | |
| TW201833326A (zh) | Ｃｄ７０結合分子及使用彼之方法 | |
| CN109476722A (zh) | 用于改善免疫细胞的功效和扩张的方法 | |
| CN117327650A (zh) | 离体bite激活的t细胞 | |
| JP2021519593A (ja) | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 | |
| JP2018533744A (ja) | サイトカイン放出症候群を予測するバイオマーカー | |
| JP2018501463A (ja) | キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用 | |
| Borowski et al. | Expression analysis and specific blockade of the receptor for human thymic stromal lymphopoietin (TSLP) by novel antibodies to the human TSLPRα receptor chain | |
| US11945876B2 (en) | Receptors providing targeted costimulation for adoptive cell therapy | |
| JP2017535273A (ja) | 免疫チェックポイントの調節因子を評価するためのシステム及び方法 | |
| IL287311B1 (en) | Antibodies and processes for their preparation | |
| WO2021142835A1 (zh) | 一种提升免疫细胞功能的增强受体 | |
| Alb et al. | Novel strategies to assess cytokine release mediated by chimeric antigen receptor T cells based on the adverse outcome pathway concept | |
| EP3956362A1 (en) | Bioassay for t-cell co-stimulatory proteins containing fc domains | |
| Moreau et al. | Control of the IL-2 responsiveness of B lymphocytes by IL-2 and IL-4 | |
| CN114656564B (zh) | 一种抗hu-OX40抗原的纳米抗体及其应用 | |
| WO2023015310A2 (en) | T-cell manufacturing methods | |
| Zhang et al. | Expression of IL-18 and its receptor in human leukemia cells | |
| Aspalter et al. | Chronic TNF-α exposure impairs TCR-signaling via TNF-RII but not TNF-RI | |
| US20230381313A1 (en) | CD16high CD57high NK-92MI Cells | |
| Scherer et al. | Characterisation of chicken OX40 and OX40L | |
| Guillet et al. | Functionally active fusion protein of the novel composite cytokine CLC/soluble CNTF receptor | |
| Nakanishi et al. | Both B151-T cell replacing factor 1 and IL-5 regulate Ig secretion and IL-2 receptor expression on a cloned B lymphoma line. | |
| Vermot-Desroches et al. | Monoclonal antibodies specific for the IL-18 receptor |